The role of LMO2 in oncogenesis was also demonstrated in two separate gene therapy trials for X-linked SCID, which were halted when five (out of 19) patients developed leukaemia. The gene discussed is LMO2; the disease is T-B+ severe combined immunodeficiency due to gamma chain deficiency.